Abstract:Objective To verify the efficacy and safety of intravesical instillation of Cystistat in reducing complications caused by intravesical chemotherapy after TUR-BT in non-muscle invasive bladder cancer patients. Methods One hundred and twenty patients who met the inclusion/exclusion criteria were enrolled into this multi-centered, randomized and blank controlled clinical study. Selected patients were randomized into the observation group and control group. TUR-BT was carried out in both groups followed by pirarubicin (THP) and Cystistat intravesical instillation in the observation group, and THP intravesical instillation alone in control group. Visual analog scale (VAS) was used as the primary efficacy variable. The secondary efficacy variables were assessments of hematuria and bladder irritation symptoms. Adverse events, laboratory tests and changes of vital signs before and after treatment were strictly observed during observation to evaluate the efficacy and safety of Cystistat.Results Demographics and baseline characteristics were comparable in both groups. The differences and the improvement rate of VAS score in the 2 groups were significant, both P＜0.01. The changes of VAS score and the improvement rate before and after treatment were (2. 24±1.70) and (92. 92±14.76) % in observation group and (0. 70±1.82) and (20. 59±87.34)% in control group respectively. According to the covariance analysis, there were significant differences in changes of VAS score between the observation group and the control group. Also, the improvement rate of VAS score was significant from visit 2. The urine frequency decreased from 9.06±4.09 to 6. 69±2.89 in observation group and increased from 8. 85±3. 32 to 10. 15±4.40 in control group, P＜0.01. There were also significant differences in changes of nocturia before and after treatment between these two groups (P＜0.01), the nocturia decreased from 2. 88±1.74 to 1. 47±1.62 in observation group and 3. 22±2.30 to 2.91±1.73 in control group, respectively. The changes of WHO assessment for hematuria,urgency and dysuria were not significantly different between the 2 groups. No Cystistat related adverse event was observed. Conclusions Cystistat combined instillation can significantly improve the VAS score of patients with chemotherapeutic agent instillation. Relief of bladder pain, frequency and nocturia are more rapidly and more durable in Cystistat combined instillation group. The improvement is more effective in patients with a high VAS score. Cystistat instillation with chemotherapeutics agents is both well tolerated and safe.

Combinations of neoadjuvant chemotherapy and transurethral resection for invasive bladder cancer

Combined Modality Therapy Following Bladder Conservation Surgery for Bladder Cancers

Preoperative Selective Internal Iliac Arterial Chemotherapy for Invasive Bladder Cancer

Combination of Hyperthermia and Intravesical Chemotherapy for the Treatment of Pt1 Stage Bladder Cancer: A Retrospectively Clinical Study.

Effects of Intravenous Chemotherapy after TURBT for High-Risk Nonmuscle Invasive Bladder Cancer: Results of a Retrospective Study

Clinical effect of iliac artery interventional chemotherapy combination with bladder perfusion for high level of bladder urothelial carcinoma

Single-dose intra-arterial infusion chemotherapy for refractory bladder cancer after transurethral resection of bladder tumor: Report of 12 cases

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Bladder Preservation by Internal Iliac Arterial Infusion Chemotherapy and Radiotherapy in Invasive Bladder Carcinoma

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

Transurethral Resection of Bladder Tumor (TURBT) Followed by Partial Hypo-Fractionated Radiotherapy Concurrent with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): Acute Toxicities of a Prospective Phase II Study

A Role of Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer Plus Hydronephrosis with or Without Pelvic Nodal Involvement.

Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Multivariant therapy for invasive,multiple and recrudescent bladder carcinoma(report of 21 cases)

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive bladder cancer

Radical Transurethral Electrovaporization for the Treatment of Invasive Bladder Cancer

Efficacy Of Immediate Instillation Combined With Regular Instillations Of Pirarubicin For Ta And T1 Transitional Cell Bladder Cancer After Transurethral Resection: A Prospective, Randomized, Multicenter Study

Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer